The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
TNM Classification of Malignant Tumours
(1987) · Springer eBooks · doi:10.1007/978-3-642-82982-6 · Cited by 16,049
Ido expression by dendritic cells: tolerance and tryptophan catabolism
Mellor, A. L., & Munn, D. H. (2004) · Nature Reviews Immunology · doi:10.1038/nri1457 · Cited by 2,341
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · cited 3×
“found IDO expression in 9 of 11 non-small cell lung cancers and in 2 of 10 small cell lung cancers by immunohistochemistry [6].”
BackgroundRegulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
Histological Typing of Lung and Pleural Tumours
Travis, W. D., Colby, T. V., Corrin, B., Shimosato, Y., & Brambilla, E. (1999) · Springer eBooks · doi:10.1007/978-3-642-60049-4 · Cited by 1,523
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
Munn, D. H., & Mellor, A. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31178 · Cited by 1,078
Endogenous kynurenines as targets for drug discovery and development
Stone, T. W., & Darlington, L. G. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd870 · Cited by 768
Brandacher, G., Perathoner, A., Ladurner, R., Schneeberger, S., Obrist, P., Winkler, C., Werner, E. R., Werner-Felmayer, G., Weiss, H. G., G√∂bel, G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1966 · Cited by 614 · cited 3×
“prognosis, indicating that IDO protein expression in tumors was a significantly prognostic variable [8].”
BackgroundOkamoto, A., Nikaido, T., Ochiai, K., Takakura, S., Saito, M., Aoki, Y., Ishii, N., Yanaihara, N., Yamada, K., Takikawa, O., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2671 · Cited by 390
Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses
Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348
Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer
Ino, K., Yoshida, N., Kajiyama, H., Shibata, K., Yamamoto, E., Kidokoro, K., Takahashi, N., Terauchi, M., Nawa, A., Nomura, S., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603477 · Cited by 248
Huang, A., Fuchs, D., Widner, B., Glover, C., Henderson, D. C., & Allen-Mersh, T. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600336 · Cited by 241
Decreased Serum Tryptophan Concentration Predicts Poor Prognosis in Malignant Melanoma Patients
Weinlich, G., Murr, C., Richardsen, L., Winkler, C., & Fuchs, D. (2007) · Dermatology · doi:10.1159/000096906 · Cited by 197
Pawlak, K., Domaniewski, T., Myśliwiec, M., & Pawlak, D. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.08.014 · Cited by 136
Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer
Karanikas, V., Ζαμανάκου, Μ., Kerenidi, T., Dahabreh, J., Hevas, A., Nakou, M., Gourgoulianis, K. I., & Germenis, A. E. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.8.4446 · Cited by 86
Tryptophan degradation in patients with gynecological cancer correlates with immune activation
Schroecksnadel, K., Winkler, C., Fuith, L. C., & Fuchs, D. (2004) · Cancer Letters · doi:10.1016/j.canlet.2004.10.033 · Cited by 85
Amirkhani, A., Heldin, E., Markides, K. E., & Bergquist, J. (2002) · Journal of Chromatography B · doi:10.1016/s1570-0232(02)00572-x · Cited by 84
Weight loss in patients with hematological neoplasias is associated with immune system stimulation
Denz, H. A., Orth, B., Weiss, G., Herrmann, R., Huber, P., WACHTER, H., & Fuchs, D. (1993) · Journal of Molecular Medicine · doi:10.1007/bf00210961 · Cited by 60
Diminished quality of life in patients with cancer correlates with tryptophan degradation
Schroecksnadel, K., Fiegl, M., Prassl, K., Winkler, C., Denz, H. A., & Fuchs, D. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0191-3 · Cited by 55
Interferon‐β affects the tryptophan metabolism in multiple sclerosis patients
Amirkhani, A., Rajda, C., Arvidsson, B., Bencsik, K., Boda, K., Seres, E., Markides, K. E., Vécsei, L., & Bergquist, J. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01041.x · Cited by 52
Possible role of cytokine‐induced tryptophan degradation in anaemia of inflammation
Weiss, G., Schroecksnadel, K., Mattle, V., Winkler, C., Konwalinka, G., & Fuchs, D. (2004) · European Journal Of Haematology · doi:10.1046/j.0902-4441.2003.00197.x · Cited by 48
Cited by
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond
Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586
Lieu, E. L., Nguyen, T., Rhyne, S., & Kim, J. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0375-3 · Cited by 818
Indole and Tryptophan Metabolism: Endogenous and Dietary Routes to Ah Receptor Activation
Hubbard, T. D., Murray, I. A., & Perdew, G. H. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.064246 · Cited by 640
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular & Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 437
Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
Fujiwara, Y., Kato, S., Nesline, M. K., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102461 · Cited by 304
Metadata
- Authors
- Suzuki, Y., Suda, T., Furuhashi, K., Suzuki, M., Fujie, M., Hahimoto, D., Nakamura, Y., Inui, N., Nakamura, H., & Chida, K.
- Venue
- Lung Cancer
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 67
- Issue
- 3
- Pages
- 361-365
- ISSN
- 0169-5002 (ISSN-L)
- OpenAlex
- W2171437874
- Cited by
- 261
- References
- 22
- FWCI
- 2.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.